AbbVievsSinovac Biotech

ABBV and SVA stock compared: price, dividend, valuation and results, from SEC filings.

AbbVie (ABBV) has a market value of $522B and Sinovac Biotech (SVA) $465M. Dividend yield: ABBV 2.35%, SVA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$522B

    SVA$465M

    ABBV is 1,122 times SVA

  • Revenue, 12 months

    ABBV$66.0B

    SVA$386M

    ABBV is 171 times SVA

  • Net income, 12 months

    ABBV$10.3B

    SVA-$60M

  • Operating margin

    ABBV32.2%

    SVA-127.0%

    159.2 points apart

  • ROIC

    ABBV25.7%

    SVA-7.9%

    33.5 points apart

  • P/E

    ABBV50.7

    SVA–

  • Dividend yield

    ABBV2.4%

    SVA0.0%

    2.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

Prices are not available right now.

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieSVASinovac Biotech

Valuation

ABBVSVA
Valuation
Price$295.03$6.47
Market value$522B$465M
Enterprise value (EV)$592B–
P/E50.7–
P/E, 5-year median57.0–
P/B–0.1
EV/EBIT27.9–
Free cash flow yield3.6%–

Results and growth

ABBVSVA
Results and growth
Revenue, 12 months$66.0B$386M
Net income, 12 months$10.3B-$60M
Free cash flow, 12 months$18.9B-$561M
Earnings per share, 12 months$5.81-$0.83
Revenue growth, year on year8.6%6.8%
Revenue growth a year, past+5.9%over 5 years-5.4%over 5 years
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVSVA
Margins and returns on capital
Gross margin73.7%67.9%
Operating margin32.2%-127.0%
Net margin15.7%-15.5%
ROIC25.7%-7.9%
ROE–-1.3%

Balance sheet

ABBVSVA
Balance sheet
Cash$10.8B$6.0B
Total debt$80.9B$506M
Net debt / EBITDA3.2–
Interest cover7.1×-49.9×

Dividends and buybacks

ABBVSVA
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92$55.00
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.5%850.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or SVA

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Sinovac Biotech?

By market value, AbbVie ($522B) is about 1,122.0 times Sinovac Biotech ($465M), at today's prices.

Which pays the higher dividend, ABBV or SVA?

The dividend yield at today's price is 2.35% for AbbVie and none for Sinovac Biotech. Over the last twelve months they paid $6.92 and $55.00 per share.

Which has the higher profit margins, AbbVie or Sinovac Biotech?

Over the last twelve months, the net margin was 15.7% for AbbVie and -15.5% for Sinovac Biotech, and the operating margin 32.2% and -127.0%. Revenue was $66.0B and $386M.

Which is the better investment, AbbVie or Sinovac Biotech?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.